Abstract
NK cells have killing activity against leukemic cells and solid cancer cells that escape from T cell recognition because of the low expression level of HLA class I molecules. This characteristic feature of NK cell recognition of target cells in contrast to T cells provides a strategy to overcome tolerance in cancer and leukemia patients. A strong alloreactive NK cell-mediated anti-leukemia effect can be induced in haploidentical hematopoietic stem cell transplantation. Also, NK cells can be expanded by several methods for adoptive immunotherapy for hematological malignancies and other malignant diseases. We review the historical role of NK cells and recent approaches to enhance the functions of NK cells, including ex vivo expansion of autologous and allogenic NK cells, checkpoint receptor blockade, and the use of memory-like NK cells and CAR-NK cells, for treatment of hematological malignancies.
| Original language | English (US) |
|---|---|
| Article number | 100678 |
| Journal | Blood Reviews |
| Volume | 44 |
| DOIs | |
| State | Published - Nov 2020 |
Bibliographical note
Funding Information:We thank Ms. R. Tsuruya and Ms. A. Morishita for their assistance. This study was supported in part by a Grant-in-Aid from the Ministry of Health, Labor and Welfare of Japan , the Mitsubishi Foundation .
Funding Information:
We thank Ms. R. Tsuruya and Ms. A. Morishita for their assistance. This study was supported in part by a Grant-in-Aid from the Ministry of Health, Labor and Welfare of Japan, the Mitsubishi Foundation.
Publisher Copyright:
© 2020 Elsevier Ltd
Keywords
- ADCC
- BiKE
- CAR-NK
- Cellular therapy
- KIR
- NK cell
- TriKE
PubMed: MeSH publication types
- Journal Article
- Review
- Research Support, Non-U.S. Gov't
